semaglutide medscape (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach Semaglutide GLP-1 Receptor Agonist Research

Compounding this plateau, placebo-controlled cardiovascular outcome trials (CVOTs) are increasingly deemed unethical in patients with established CVD, as current standards of care now include agents with proven cardiovascular efficacy, namely GLP-1RA and SGLT-2 inhibitors

Protein + hydration focus Supportive habits that can make the program easier to tolerate

Sipping water throughout the day rather than consuming large amounts with meals is preferred, as large fluid volumes during meals can worsen gastric distension

[DOI] [PubMed] [Google Scholar] 31.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, et al

Even experienced patients occasionally make injection errors that can affect medication delivery or cause discomfort